Skip to main content

Table 1 Characteristics of all included patients

From: Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings

Variables Plaques ( +)
n = 121 (17.3%)
Plaques (-)
n = 580 (82.7%)
P value
Age (median, IQR) 74 (70–78) 72 (65–77)  < 0.001
Sex, Male 112 (92.5%) 313 (54.0%)  < 0.001
Smoking history 111 (91.7%) 342 (59.0%)  < 0.001
Preoperative CT findings
 Radiological emphysematous changes (GS ≥ 5 points) 54 (44.6%) 138 (23.8%)  < 0.001
 Radiological IP findings 39 (32.2%) 115 (19.8%) 0.004
 Whole tumor size (mm) (median, IQR) 21 (15–31) 20 (14–28) 0.024
 Solid tumor size (mm) (median, IQR) 19 (12–28) 15 (10–25) 0.013
 SUVmax 5.4 (2.4–13.0) 2.6 (1.3–6.3)  < 0.001
Pulmonary function
 %VC (%) (median, IQR) 95.9 (86.4–109.7) 102.5 (89.7–113.8) 0.010
 FEV1/FVC (%) (median, IQR) 75.8 (67.2–85.3) 77.8 (71.6–85.6) 0.007
Clinical stage    0.561
 IA1 24 (19.8%) 153 (26.3%)  
 IA2 41 (33.9%) 188 (32.4%)  
 IA3 22 (18.2%) 92 (15.8%)  
 IB 15 (12.4%) 64 (11.0%)  
 IIA 3 (2.5%) 10 (1.7%)  
 IIB 11 (9.1%) 41 (7.1%)  
 IIIA 5 (4.1%) 25 (4.3%)  
 IIIB 0 (0%) 7 (1.2%)  
Surgical procedure    0.676
 Wedge resection 31 (25.6%) 180 (31.0%)  
 Segmentectomy 17 (14.1%) 78 (13.4%)  
 Lobectomy 71 (58.7%) 315 (54.3%)  
 Pneumonectomy 2 (1.7%) 7 (1.2%)  
Invasive characteristics
 LY 14 (11.6%) 57 (9.8%) 0.569
 V 13 (10.7%) 54 (9.3%) 0.631
PL    0.249
 PL1 13 (10.7%) 49 (8.5%)  
 PL2 3 (2.5%) 14 (2.4%)  
 PL3 7 (5.8%) 14 (2.4%)  
Histology     < 0.001
 Adenocarcinoma 66 (54.5%) 460 (79.3%)  
 Squamous cell carcinoma 47 (38.8%) 91 (15.7%)  
 Adenosquamous carcinoma 2 (1.7%) 14 (2.4%)  
 Sarcomatoid carcinoma 1 (0.8%) 6 (1.0%)  
 LCNEC 4 (3.3%) 7 (1.2%)  
 Lymphoepithelioma-like carcinoma 1 (0.8%) 1 (0.2%)  
 Mucoepidermoid carcinoma 0 (0%) 1 (0.2%)  
Pathological stage    0.021
 0 5 (4.1%) 49 (8.4%)  
 IA1 26 (21.5%) 171 (29.5%)  
 IA2 24 (19.8%) 113 (19.5%)  
 IA3 16 (13.2%) 74 (12.8%)  
 IB 20 (16.5%) 76 (13.1%)  
 IIA 5 (4.1%) 8 (1.4%)  
 IIB 10 (8.3%) 50 (8.6%)  
 IIIA 15 (12.4%) 32 (5.5%)  
 IIIB 0 (0%) 7 (1.2%)  
Recurrence 28 (23.1%) 104 (17.9%) 0.192
Death from any cause 37 (30.6%) 91 (15.7%)  < 0.001
Death from lung cancer 16 (13.2%) 49 (8.5%) 0.115
Death from respiratory disease 12 (9.9%) 21 (3.6%) 0.007
Death from causes other than lung cancer and respiratory disease 9 (7.4%) 21 (3.6%) 0.079
  1. IQR interquartile range, CCI Charlson comorbidity index, CT computed tomography, IP interstitial pneumonia, GS Goddard score, SUV maximum standardized uptake value, VC vital capacity, FEV1.0 forced expiratory volume in one second, LY lymphatic invasion, V vascular invasion, PL pleural invasion, LCNEC large cell neuroendocrine carcinoma